Abstract:Selectivity profiling is key for assessing the pharmacological properties of multi-target drugs. We have developed a cell-based and barcoded assay encompassing ten druggable targets, including G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs), nuclear receptors, a protease as well as their key downstream pathways and profiled 17 drugs in living cells for efficacy, potency, and side effects. Notably, this multiplex assay, termed safetyProfiler assay, enabled the simultaneous assessment of multiple target and pathway activities, shedding light on the polypharmacological profile of compounds. For example, the neuroleptics clozapine, paliperidone, and risperidone potently inhibited primary targets DRD2 and HTR2A as well as cAMP and calcium pathways. However, while paliperidone and risperidone also potently inhibited the secondary target ADRA1A and mitogen-activated protein kinase (MAPK) downstream pathways, clozapine only exhibited mild antagonistic effects on ADRA1A and lacked MAPK inhibition downstream of DRD2 and HTR2A. Furthermore, we present data on the selectivity for bazedoxifene, an estrogen receptor antagonist currently undergoing clinical phase 2 trials for breast cancer, on MAPK signaling. Additionally, precise potency data for LY2452473, an androgen receptor antagonist, that completed a phase 2 clinical trial for prostate cancer, are presented. The non-selective kinase inhibitor staurosporine was observed to potently inactivate the two RTKs EGFR and ERBB4 as well as MAPK signaling, while eliciting stress-related cAMP responses. Our findings underscore the value of comprehensive profiling in elucidating the pharmacological properties of established and novel therapeutics, thereby facilitating the development of novel multi-target drugs with enhanced efficacy and selectivity.

Label-Free Cell Phenotypic Assays for Assessing Drug Polypharmacology.

Methods to Profile the Macromolecular Targets of Small Compounds.

A Proteomic Landscape of Pharmacologic Perturbations for Functional Relevance

Label-free target protein characterization for small molecule drugs: recent advances in methods and applications

Polypharmacological profiling across protein target families and cellular pathways using the multiplexed cell-based assay platform safetyProfiler reveals efficacy, potency and side effects of drugs

Kinetic cellular phenotypic profiling: prediction, identification, and analysis of bioactive natural products.

Phenotypic Assessment and Ligand Screening of ETA/ETB Receptors with Label-Free Dynamic Mass Redistribution Assay

Drug evaluations using a novel microphysiometer based on cell-based biosensors

Label-Free Quantification of Molecular Interaction in Live Red Blood Cells by Tracking Nanometer Scale Membrane Fluctuations.

Exploiting Cell-Based Assays to Accelerate Drug Development for G Protein-Coupled Receptors

A novel microphysiometer based on MLAPS for drugs screening.

Polymer membrane and cell models for drug discovery.

Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs

Image-Based Annotation of Chemogenomic Libraries for Phenotypic Screening

Image based annotation of Chemogenomic Libraries for Phenotypic Screening

Polypharmacological Drug Design Guided by Integrating Phenotypic and Restricted Fragment Docking Strategies

Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery

Multiplexed profiling of intracellular protein abundance, activity, interactions and druggability with LABEL-seq

Multiplexed, multimodal profiling of the intracellular activity, interactions, and druggability of protein variants using LABEL-seq

Identifying The Proteins To Which Small-Molecule Probes And Drugs Bind In Cells

Label-free Cell Phenotypic Profiling Identifies Pharmacologically Active Compounds in Two Traditional Chinese Medicinal Plants